Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic ancestry in kidney cancer: Correlations with clinical and molecular features
    Journal Article

    Kotecha, R. R.; Knezevic, A.; Arora, K.; Bandlamudi, C.; Kuo, F.; Carlo, M. I.; Fitzgerald, K. N.; Feldman, D. R.; Shah, N. J.; Reznik, E.; more...
    Cancer (2024)

    Fulltext@MSK | Save
  • Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Jacobi, R.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
    Meeting Abstract

    Shah, N. J.; Campbell, M. T.; Mao, S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H.; Keshava-Prasad, H.; Hoimes, C. J.; Hussain, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
    Meeting Abstract

    Voss, M. H.; Garmezy, B.; Kim, S. H.; Rey, J. P. M.; Mansinho, A. B.; Rodriguez-Vida, A.; Oliveira, J.; van Dongen, M.; Medina Rodríguez, L.; Negrier, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • LITESPARK-012: Pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
    Review

    Choueiri, T. K.; Powles, T.; Voss, M. H.; Plimack, E. R.; Gurney, H.; Song, Y.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
    Future Oncology (2023)

    Fulltext@MSK | Save
  • Functional and translational consequences of immunometabolic coevolution in ccRCC
    Meeting Abstract

    Reznik, E.; Tang, C.; Xie, A.; Liu, E. M.; Kuo, F.; Kim, M.; Golkaram, M.; Chen, Y.; Gupta, S.; Motzer, R.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types
    Meeting Abstract

    Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Beckermann, K.; Campbell, M. T.; Haas, N. B.; Ornstein, M. C.; Gao, X.; Mao, S. S.; Hammers, H. J.; George, S.; Nelson, A. A.; Gourdin, T. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save